Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects, male or female, aged 18 to 75 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control~2. Subject has glycosylated hemoglobin, HbA1C, ≤ 12%~3. Subject with diagnosis of neuropathic foot ulcer by 10g monofilament test~4. Subject has adequate vascular perfusion of the affected limb, confirmed by Ankle-Brachial Index (ABI) ≥ 0.65 and ≤ 1.3~5. Presence of at least one DFU that meets all of the following criteria:~   1. A full-thickness ulcer of Grade A1 as per Texas classification system;~  2. Ulcer is located below or up to 5 cm above the malleoli (excluding ulcers between the toes);~  3. Ulcer size (area) is ≥ 2 cm2 and ≤ 15 cm2 (post-debridement);~  4. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot, post-debridement;~  5. No exposed bone, tendon, muscle, ligament or joint capsule, and no tunneling, undermining, or sinus tracts;~  6. Unresponsive to ulcer care and open for at least 6 weeks at the time of the Screening Visit;~  7. Ulcer is non-infected as determined by clinical assessment and complete hemogram;~  8. Ulcer has a clean, granulating base free of adherent slough to the greatest extent possible as per Investigator;~  9. Ulcer area reduction \< 30% from the Screening Visit to Baseline visit~6. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Investigator~7. Subject, if female of child-bearing potential, has a negative urine pregnancy test at Screening and willing to use acceptable methods of contraception (birth control pills, barriers) or abstinence throughout the Study~8. Subject is able and willing to comply with Study procedures including the use of an off-loading device (as applicable for the location of the ulcer) and adhere to protocol during the Study in the opinion of Investigator~9. A Subject or LAR agrees to sign informed consent form and allow audio visual recording of consent, if applicable~Exclusion Criteria:~1. Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis~2. Subjects with more than three ulcers below knee~3. Subjects with Target Ulcer requiring off-loading that cannot be effectively off-loaded; or unable to tolerate the off-loading method~4. Subject has ulcers caused by a disease other than diabetes, e.g., fungal ulcerations, malignant ulcerations, and ulcerations due to venous or arterial insufficiency, or due to hematological disorders, in the opinion of the Investigator~5. Ulcer, about which the Investigator is suspicious for cancer~6. Subjects with a gangrenous or ischemic ulcer~7. Subject with ulcer that in the opinion of the Investigator, may need amputation~8. Subject with Target ulcer where wound measurement is not possible, such as ulcers between toes~9. Body mass index (BMI) \> 40 kg/m2~10. Laboratory values at Screening of:~    1. Hemoglobin \< 10.0 g/dL~   2. White Blood Cells (WBC) \< 2.0 X 109 cells/L~   3. Liver function studies \[Total bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT)\] \> 3x the upper limit of normal~   4. Albumin \< 2.5 g/dL~   5. eGFR \< 25 mL/min~11. Presence of any existing clinically significant medical condition(s) that, in the opinion of the Investigator, could interfere with wound healing~12. Subject has received or is currently receiving or scheduled to receive any medication or therapies during the course of the Study that will modulate wound healing~13. Subject with intolerance to β-blockers at any time in the past~14. Has any other factor which may, in the opinion of the Investigator, compromise participation and/or follow-up in the Study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Galnobax® 14% gel plus SoC (Type: ACTIVE_COMPARATOR): Galnobax 14% gel along with Standard of Care (SoC) will be administered twice daily (150 subjects)
- SoC Only (Type: SHAM_COMPARATOR): Only Standard of Care will be administered twice daily (150 subjects)
- Vehicle plus SoC (Type: PLACEBO_COMPARATOR): Vehicle gel along with Standard of Care (SoC) will be administered twice daily (50 subjects)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete